{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-000831","form_type":"8-K/A","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.440717+00:00","generated_at":"2026-06-29T21:52:37.443129+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass Therapeutics merger with Trigr completed; Trigr had $99k cash, $15.8M deficit","bullets":["Trigr audited 2020: cash $99k, total liabilities $2.57M, net loss $2.11M, accumulated deficit $15.8M; going concern doubt.","Trigr unaudited Q1 2021: cash $4.3M, net income $5.6M from $7M licensing revenue to Elpiscience.","Merger consideration: 10.27M Compass shares at $4.90/share (~$50.3M) plus up to $9M earnout.","Trigr lead asset CTX-009 licensed to Elpiscience for Greater China; $7M upfront, up to $110M milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-000831","json":"https://secwatch.observer/filing/0000950170-21-000831.json","markdown":"https://secwatch.observer/filing/0000950170-21-000831.md","text":"https://secwatch.observer/filing/0000950170-21-000831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000095017021000831/0000950170-21-000831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000095017021000831/cmpx-20210625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:52:37.443129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}